60325 Frankfurt am Main, de
+49 (69) 975837-84
NextGen Alpha prepares artificial intelligence investor conference
Investors will gain a high level of comfort from their new found understanding regarding important matters such as the basics of how some artificial intelligence technologies seek to mimic the neural networks of the human brain, how some managers use not only one but use a range of existing and evolutionary AI technologies, how AI impacts fund investment process and how AI has the potential to drive down costs and help create alpha in markets which are already crowded and highly efficient.
Additionally, investors will have a clear understanding that artificial intelligence as applied to fund management and involves limited to no human intervention in the investment process is in no way related to or has evolved from traditional "quant" oriented approaches and technologies.
Managing Partner of ACATIS, Dr. Hendrik Leber, states, "we are excited to work with NextGen to deliver a unique conference format that provides industry peers a forum to share experiences and capabilities and how proprietary AI "deep learning" technological developments will benefit clients and impact our thinking in terms of the range of products and services we offer".
Managers and investors will have an opportunity during the conference to connect and engage directly.
The one-day event is by invitation only to be held March 30, 2017 at the Sheraton Frankfurt, Airport Hotel & Conference Center. Space is limited and reserved for qualified professional/institutional investors. Pre-registration is required (www.nextgen-alpha.com).
The conference is the first in a series of planned NextGen Alpha events and activities aimed at fostering visibility, exposure and connectivity to the benefit of AI investors and investment management industry participants.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.